99% purity cagrilintide 5mg+Samaglutide 5mg high quality 10mg/vial Jack
59 Inquiries
1415456-99-3
Pharmaceutical
99%
Hong Kong
HUATAI
10vials
2026-11-08
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceCagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia[1-2].Basic Info
-
Product Name:
Cagrilintide
Other Name:Cagrilintide;Cargliptin;Caglitide;Cagrilintide acetate;Cagrilintide peptide;Cagrilintide 5mg 10mg 15mg;Cagrilintide(Acetate form);Kagliptin
CAS No.:1415456-99-3
Molecular Weight:0
EC Number:206-141-6
Color/Form:White to off-white
Categories:
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Location:
1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA
-
-
Inquiry History59 Inquiries
Country Product Purchase Quantity Date Posted 
United Kingdom
Cagrilintide
10 MG Jul 31, 2026 
France
Cagrilintide
10 MG May 22, 2026 
Australia
Cagrilintide
4 MT Mar 9, 2026 
United States
Cagrilintide
15 MG Feb 25, 2026
United States
Cagrilintide
10 PCS Dec 27, 2025
United States
Cagrilintide
2 MT Dec 21, 2025
United States
Cagrilintide
100 MG Oct 28, 2025
United States
cagrilintide
2 MT Aug 8, 2025 
Philippines
Retatrutide
5 MG Aug 5, 2025 
China
Cagrilintide
100 G May 6, 2025
United States
cagrilintide
5 MG Feb 18, 2025
United States
Cagrilintide
3 MT Feb 7, 2025
United States
Cagrilintide
100 Nov 12, 2024
United States
Cagrillintide Lyophilized powder
100 MG Jul 4, 2024
United States
Cagrillintide Lyophilized powder
1000 MG Apr 20, 2024
United States
Cagrlintide
1 MT Jul 31, 2026
United Kingdom
cagrilintrude
20 MG Jul 21, 2026
United States
Cagrilintide
1 KG Jul 17, 2026
United States
Cagrilintide
30 MG May 26, 2026
United Kingdom
CAGRILLINTED
10 May 3, 2026 Post an enquiry for this product